Teligent Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented)

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%.

As quoted in the press release:

“Betamethasone Dipropionate Lotion USP (Augmented), 0.05% is Teligent’s first FDA approval in 2018,’’ commented Jason Grenfell-Gardner, President and CEO of the Company.  “This approval shows Teligent’s commitment to delivering on our high-value pipeline and continuing the growth trajectory of the Company. We expect to launch this product in the first quarter of 2018.”

Click here to read the full press release.